No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Hualü Biological (300970.SZ): Buyback completed, having repurchased a total of 1.95% of shares.
On March 4, Glonghui reported that Hualü Biotechnology (300970.SZ) announced that as of the date of disclosure of this announcement, the share repurchase period has expired, and the company's share repurchase plan has been completed. As of the date of disclosure of this announcement, the company repurchased 2,346,600 shares through the Shenzhen Securities Exchange's stock trading system via centralized bidding, accounting for 1.95% of the company's current total share capital, with a highest Fill Price of 13.83 yuan/share, a lowest Fill Price of 12.22 yuan/share, and a total amount of 30.0046 million yuan (excluding transaction fees).
Express News | Hua Green Biological: Expected net income loss of 38 million to 56 million yuan in 2024.
Hualu Biotech: 2024 Annual Performance Forecast
Express News | This month, 25 listed companies announced that Shareholders had reduced their Shareholding to 5% or below. The next day, Shanghai New World hit the limit down.
Hualv Biology (300970.SZ): Has cumulatively repurchased 1.95% of the shares.
On December 2, Gelonghui reported that Hua Lv Bio (300970.SZ) announced that as of November 30, 2024, the company has repurchased 2,346,600 shares through the stock trading system of the Shenzhen Stock Exchange via centralized bidding, accounting for 1.95% of the company's current total share capital. The highest fill price was 13.83 yuan per share, the lowest fill price was 12.22 yuan per share, and the total transaction amount was 30.0046 million yuan (excluding transaction fees).
October 29th A-share investment lightning rod︱West Pharmaceutical: Shareholders China National Pharmaceutical Group and Hangzhou Chuanhe plan to jointly reduce their shareholding by no more than 3%.
Observing Defense: Stocks may be subject to other risk warnings.
